CEO Marino Garcia Sells $17.95M in Dianthus Stock Near 52-Week High
DNTH has more than doubled off its 52-week low of $18.08.
Summary
Dianthus Therapeutics CEO Marino Garcia sold $17.95 million worth of shares on August 7, 2026, exercising options at $8.44 and selling at prices between $107.49 and $110.76. The sale was part of a 10b5-1 plan and adds to a recent pattern of insider selling.
Key Events · Ownership and Investor Activity · DNTH
-
CEO Sells $17.95M in Stock
Marino Garcia, CEO and President, exercised 166,000 options at $8.44 and sold all resulting shares for $17.95 million, at prices ranging from $107.49 to $110.76.
-
10b5-1 Plan Execution
The sale was executed under a Rule 10b5-1 trading plan adopted on May 8, 2026, indicating the transaction was pre-planned.
-
Near 52-Week High
The sale occurred with the stock trading near its 52-week high of $114.55, allowing the CEO to lock in substantial gains.
-
Ongoing Insider Selling Pattern
This sale adds to a 90-day net insider selling total of approximately $8 million, with multiple officers filing Form 144s recently.
Analysis · DNTH · Life Sciences
CEO and President Marino Garcia exercised 166,000 options at $8.44 and immediately sold all resulting shares for $17.95 million, locking in gains near the stock's 52-week high. The sale was executed under a pre-existing 10b5-1 plan adopted in May 2026, which reduces the signaling weight but does not eliminate the optics of a key insider monetizing a significant position. This follows a pattern of insider selling over the past 90 days, with net insider sales of nearly $8 million prior to this transaction. While the company recently reported strong clinical data and a robust cash position, the CEO's decision to sell a large block of shares at elevated prices may raise questions about near-term valuation.
At the time of this filing, DNTH was trading at $108.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $18.08 to $114.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.